← Leaderboards
Jason Huse
Sloan-Kettering Inst Can Research
$6,410,852
Attributed
$9,982,319
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,982,319 · 7
By mechanism
R01$6,826,856 · 2
P50$2,625,153 · 3
R21$460,940 · 1
U54$69,370 · 1
Top collaborators
- Jonine Lisa Bernstein5 shared
- Melissa L Bondy5 shared
- Jiaqian Wu1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Scott W Lowe$63,222,126
- Samuel Singer$8,089,401
- Michael Kharas$18,485,709
- Xiang Zhang$12,735,442
- Ross L Levine$31,715,816
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularTumorMalignant GliomaGliomaSamplingBiologyResourcesProteinsBrain NeoplasmsMalignant Neoplasm Of BrainCollaborationsGlioblastomaVariantSpecimenMutationInsightPathogenesisDesignBehaviorCellsCell LineCohortBaseInnovation
Grant awards (25)
Investigating the impact of glioma-associated germline risk alleles on neurodevelopmental trajectories$460,940
R21 · FY2025 · NS · contact PI
Pathology and Biorepository Core (Core B)$160,940
P50 · FY2025 · CA · contact PI
Pathology and Biorepository Core (Core B)$166,994
P50 · FY2024 · CA · contact PI
Characterizing germline and somatic alterations by glioma subtypes and clinical outcome$923,381
R01 · FY2023 · CA
Characterizing heterochromatin dysfunction as a driving alteration in cancer$358,680
R01 · FY2023 · CA · contact PI
Characterizing germline and somatic alterations by glioma subtypes and clinical outcome$1,498,836
R01 · FY2022 · CA
Deciphering Germline and Somatic Genomic Landscape of Gliomas in Black and Hispanic Minority Groups$430,605
P50 · FY2022 · CA · contact PI
Characterizing heterochromatin dysfunction as a driving alteration in cancer$358,680
R01 · FY2022 · CA · contact PI
Pathology and Biorepository Core (Core B)$152,588
P50 · FY2022 · CA · contact PI
Characterizing germline and somatic alterations by glioma subtypes and clinical outcome$1,529,801
R01 · FY2021 · CA
Deciphering Germline and Somatic Genomic Landscape of Gliomas in Black and Hispanic Minority Groups$378,098
P50 · FY2021 · CA · contact PI
Characterizing heterochromatin dysfunction as a driving alteration in cancer$366,000
R01 · FY2021 · CA · contact PI
Pathology and Biorepository Core (Core B)$133,166
P50 · FY2021 · CA · contact PI
Deciphering Germline and Somatic Genomic Landscape of Gliomas in Black and Hispanic Minority Groups$451,357
P50 · FY2020 · CA · contact PI
Characterizing heterochromatin dysfunction as a driving alteration in cancer$366,000
R01 · FY2020 · CA · contact PI
Pathology and Biorepository Core (Core B)$151,981
P50 · FY2020 · CA · contact PI
Characterizing germline and somatic alterations by glioma subtypes and clinical outcome$656,870
R01 · FY2019 · CA
Deciphering Germline and Somatic Genomic Landscape of Gliomas in Black and Hispanic Minority Groups$446,671
P50 · FY2019 · CA · contact PI
Characterizing germline and somatic alterations by glioma subtypes and clinical outcome$402,608
R01 · FY2019 · CA
Characterizing heterochromatin dysfunction as a driving alteration in cancer$366,000
R01 · FY2019 · CA · contact PI
Pathology and Biorepository Core (Core B)$152,753
P50 · FY2019 · CA · contact PI
Pathology Core$15,930
U54 · FY2015 · CA · contact PI
Pathology Core$17,703
U54 · FY2014 · CA · contact PI
Pathology Core$17,999
U54 · FY2013 · CA · contact PI
Pathology Core$17,738
U54 · FY2012 · CA · contact PI